MedTrace Logo

Protective Effect of EPA on Cardiovascular Events

NCT00231738 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18000

Last updated 2015-11-20

No results posted yet for this study

Summary

The purpose of this study was to test the hypothesis that the long-term use of highly (\>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.

Conditions

  • Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease

Interventions

DRUG

Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)

Sponsors & Collaborators

  • Mochida Pharmaceutical Company, Ltd.

    collaborator INDUSTRY

  • Kobe University

    lead INDUSTRY

Principal Investigators

  • Mitsuhiro Yokoyama, MD, PhD.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-11-30
Completion
2004-11-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00231738 on ClinicalTrials.gov